Tirzepatide
Definition
Tirzepatide (brand names Mounjaro for type 2 diabetes, Zepbound for obesity) is a once-weekly injectable medication that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-mechanism approach produces additive effects on appetite suppression, insulin sensitivity, fat metabolism, and metabolic regulation. In the SURMOUNT clinical trial program, participants achieved average weight losses of 15 to 22.5% of body weight over 72 weeks — the highest efficacy data of any FDA-approved weight loss medication to date. Tirzepatide also improves triglycerides, blood pressure, A1C, and visceral fat independent of weight loss alone.
Frequently Asked Question
Why Tirzepatide Matters
How Spokmed Company Uses It
Tirzepatide may be prescribed at SPOKEmed when clinically indicated as part of a supervised metabolic protocol. Michelle Middleton, PA-C individualizes dosing and monitors each patient through follow-up testing and health coaching. Nutritional support — including structured protein intake and meal timing — is integrated alongside the medication to protect lean muscle mass and support durable outcomes.